SCHEMBL3914904

SCHEMBL3914904

CSCCC1NC2(CCN(S(=O)(=O)c3ccc([N+](=O)[O-])cc3)CC2)N(Cc2ccccc2[N+](=O)[O-])C1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ACHE P22303 1/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
HSP90AA1 P07900 1/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
NR3C1 P04150 1/20 0.34
POLB P06746 1/20 0.34
MMP2 P08253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3916138 0.89 PKM (0.39) ALDH1A1SMN1; SMN2ACHEMAPTTDP1
SCHEMBL3920596 0.84 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2ACHEKDM4EMAPT
SCHEMBL1802615 0.81 ALDH1A1 (0.41) ALDH1A1ACHEKDM4ETDP1KMT2A
SCHEMBL1800359 0.78 SIGMAR1 (0.41) ALDH1A1SMN1; SMN2ACHEKDM4EMAPT
SCHEMBL1801397 0.78 ACHE (0.39) ALDH1A1ACHEKDM4EMAPTTDP1
SCHEMBL1800360 0.77 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2ACHEKDM4EMAPT
SCHEMBL1802738 0.77 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2KDM4EMAPTKMT2A
SCHEMBL3918144 0.77 MMP2 (0.53) ALDH1A1SMN1; SMN2KDM4EMAPTKMT2A
SCHEMBL1802774 0.77 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2KDM4EMAPTKMT2A
SCHEMBL1798457 0.77 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2ACHEKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US claimed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP claimed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US disclosed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP disclosed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed
EP-1730144-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5|DECAN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2006-12-13 EP disclosed
WO-2005095398-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds THPO, UGT1A8, UGT1A4 ALDH1A1 199/4885SMN1; SMN2 1274/4885ACHE 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.